Also this week in Pfizer-related Maryland biotech news: Gaithersburg-based GlycoMimetics Inc. collected a $15 million payment from the pharma giant stemming from its license agreement for the sickle cell anemia drug rivipansel.
GlycoMimetics in 2011 inked the Pfizer partnership, worth up to $340 million, to develop rivipansel (then just called GMI-1070) as a treatment for a complication of sickle cell disease called vaso-occlusive crisis.